NCT02011334View on ClinicalTrials.gov

A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.

PHASE3CompletedINTERVENTIONAL
Enrollment

285

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Rheumatoid Arthritis
Interventions
DRUG

tocilizumab [RoActemra/Actemra]

162 mg will be administered once weekly by subcutaneous injection.

Trial Locations (25)

4001

Maracaibo

4102

Punto Fijo

5000

Córdoba

10208

Santo Domingo

58070

Morelia

97000

Mérida

74110010

Goiânia

C1015ABO

Buenos Aires

C1426AAL

Buenos Aires

C1428DQG

Buenos Aires

C1055AAF

C. A. B. A.

S2000PBJ

Rosario

78025-000

Cuiabá

36036-330

Juiz de Fora

20950-000

Rio de Janeiro

90035-003

Porto Alegre

90035-170

Porto Alegre

90610-000

Porto Alegre

01244-030

São Paulo

04026-000

São Paulo

05437-010

São Paulo

Unknown

Bogota D.C.

Bucaramanga

Medellín

06726

Mexico City

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02011334 - A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs. | Biotech Hunter | Biotech Hunter